Highlights from the Hill

April 2016

In this Issue

- Public Policy Institute and Teens Speak Up!
- Cannabis Letter to DEA
- In The States

Advocates Speak Up for Epilepsy Community on Capitol Hill

Nearly 200 teens, parents, affiliates, and volunteers gathered for the Epilepsy Foundation’s annual Public Policy Institute and Teens Speak Up! (PPI/TSU) conference held April 17-19.

Representatives from 33 states and 36 affiliates participated in a day and a half of advocacy training that culminated with an awesome sunny Hill day on April 19. Conference attendees learned about the importance of raising awareness about the challenges of living with epilepsy with their elected officials and heard from experts about our policy priorities. Teens and their families, and affiliate staff and volunteers shared their personal stories and spoke up for the epilepsy community through more than 220 Congressional visits. TSU participants also made a year-long commitment to the Year of Service campaign, which calls on them to be advocates for

While on Capitol Hill our advocates spoke with their Representatives and Senators and their staff about funding for epilepsy at the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), removing federal barriers to cannabis research, creating a system to gather additional data regarding neurological conditions to help further research, and preserving the six protected classes policy in Medicare Part D so that beneficiaries living with epilepsy who rely on this program can have meaningful access to epilepsy medications.

Thank you to all of our advocates who attended the conference and shared their story to help move forward policies that will benefit the epilepsy community. If you want to learn more about our advocacy work, go to [www.epilepsy.com/advocacy](http://www.epilepsy.com/advocacy).

---

**Patient Groups Urge DEA to Lift Barriers to Cannabis Research**

Yesterday, April 27, 14 organizations representing Americans living with chronic and rare health conditions joined the Epilepsy Foundation in a letter to the Drug Enforcement Administration (DEA) expressing our support for removing federal barriers to cannabis research.

Moving cannabis from Schedule I in the Controlled Substances Act (CSA) would pave the way for greater research and new treatments. Currently it is difficult for scientists and researchers to organize clinical trials involving cannabis because it is a Schedule I substance and only the National Institute for Drug Abuse (NIDA) can cultivate cannabis for medical research. There are also additional costs and infrastructure requirements due to the Schedule I status that can limit innovation and investment in medical benefit research.

To read the full letter and press release, go to [www.epilepsy.com/cannabis](http://www.epilepsy.com/cannabis).

---

**In The States**

**Pennsylvania Becomes 24th State to Pass Medical Cannabis**

On April 17, Pennsylvania Governor Tom Wolf signed SB 3, which will create a comprehensive medical cannabis program in the state. Pennsylvania is now the 24th state to pass legislation creating access to the full cannabis plant for medical purposes, which will hopefully lead to safe, legal access to cannabis treatments for people living with epilepsy and other chronic conditions.

---

Email us at [KSU@efa.org](mailto:KSU@efa.org)
Follow us on Twitter at [EpilepsyFdn](https://twitter.com/EpilepsyFdn)
Like us on Facebook at [Epilepsy Foundation of America](https://www.facebook.com/EpilepsyFoundationofAmerica)